About this condition
Limited cutaneous systemic sclerosis (lcSSc), still widely known by the older term “CREST Syndrome,” is a subtype of scleroderma characterized by skin involvement limited to areas distal to the elbows and knees, plus the face. The acronym CREST stands for the five characteristic features: Calcinosis (calcium deposits in skin), Raynaud’s phenomenon (vasospastic response to cold), Esophageal dysmotility (swallowing problems and reflux), Sclerodactyly (skin tightening in fingers), and Telangiectasia (dilated capillaries).
Limited scleroderma often progresses more slowly than diffuse systemic sclerosis but can still produce serious organ complications — particularly pulmonary arterial hypertension (which has poor prognosis without treatment), severe esophageal disease requiring intervention, digital ulcerations from chronic Raynaud’s, and gastrointestinal dysmotility throughout the GI tract.
SSDI evaluation falls under Listing 14.04 (systemic sclerosis), which doesn’t distinguish between limited and diffuse subtypes — both qualify on the same evidentiary path. The strongest claims involve documented pulmonary involvement (HRCT, PFTs with reduced DLCO, right heart catheterization for pulmonary hypertension), digital ulcerations, severe Raynaud’s with significant cold-exposure limits, and esophageal dysmotility documented on manometry.
What the SSA Listing requires (Listing 14.04)
What wins this case at hearing in Colorado
-
Diagnostic serology
Anti-centromere antibody (highly specific for limited scleroderma), ANA, sometimes anti-Th/To. The serologic profile distinguishes limited from diffuse subtypes.
-
Pulmonary evaluation
HRCT chest for interstitial lung disease (less common in limited than diffuse, but does occur); PFTs with DLCO (often reduced before clinical symptoms); echocardiogram screening for pulmonary hypertension; right heart catheterization if PH suspected.
-
GI involvement documentation
Esophageal manometry showing dysmotility, upper endoscopy findings (Barrett’s, strictures, GERD), small bowel imaging if dysmotility suspected lower in the GI tract.
-
Skin and extremity documentation
Modified Rodnan skin score, photographic record of skin changes, nailfold capillaroscopy, digital ulcer history with treatment records, calcinosis imaging.
-
Rheumatologist treatment records
Records of disease-modifying therapy (mycophenolate, cyclophosphamide if pulmonary involvement; ACE inhibitors for renal protection; calcium channel blockers / phosphodiesterase inhibitors for Raynaud’s; PPI for esophageal disease).
-
Functional capacity statement
Treating rheumatologist’s opinion on workday functioning: cold-exposure restrictions, dexterity limits from sclerodactyly, GI symptom impact on meal scheduling, exertion tolerance with pulmonary involvement.
Colorado-specific factors
Colorado has specialized scleroderma care at UCHealth Anschutz Medical Campus (rheumatology, pulmonary hypertension program), National Jewish Health (pulmonary expertise specifically for scleroderma-related lung disease), and private rheumatology practices in Denver, Boulder, and Colorado Springs. Documentation for Colorado CREST patients tends to be thorough when patients access these specialty programs.
One Colorado-specific issue worth raising at hearing: Colorado’s cold winters substantially worsen Raynaud’s phenomenon, and outdoor work environments are typically incompatible with severe CREST. Document how seasonal weather and altitude affect symptoms — useful context for the vocational analysis.
What disqualifies a claim (honestly)
Limited scleroderma cases that may need additional development: very early disease without organ involvement; isolated Raynaud’s without other CREST features documented; mild esophageal symptoms well-controlled by PPI; no documented constitutional symptoms (fatigue, malaise, weight loss). Strong CREST claims usually involve at least pulmonary or significant GI involvement plus the characteristic constitutional symptoms.
Frequently asked questions about SSDI for Limited Scleroderma (CREST Syndrome) in Colorado
Is limited scleroderma evaluated differently than diffuse scleroderma for SSDI?
No — both fall under Listing 14.04 (systemic sclerosis) and follow the same evidentiary path. The Listing requires either organ involvement to at least moderate severity plus constitutional symptoms, OR repeated manifestations with marked limitation in daily functioning. Limited scleroderma can meet either path when properly documented.
My CREST is mostly Raynaud's and esophageal symptoms. Does that qualify?
It can. Severe Raynaud’s with documented digital ulcerations plus significant esophageal dysmotility affecting nutrition or causing chronic GERD with complications can meet Listing 14.04. The documentation must address both organ-system involvement AND constitutional symptoms (fatigue, malaise, weight loss).
I have pulmonary hypertension from limited scleroderma. Does that automatically qualify me?
Pulmonary hypertension secondary to scleroderma can meet either Listing 14.04 (immune system) or Listing 4.02 (chronic heart failure) depending on severity and documentation. Right heart catheterization data, 6-minute walk test results, and functional class are central to the analysis. PAH cases are typically strong SSDI claims.
How long does a CREST/limited scleroderma SSDI claim take in Colorado?
18 to 28 months from initial application through ALJ hearing in Colorado in 2026. Strong cases with documented multi-organ involvement sometimes approve at initial application or reconsideration without requiring a hearing.